German Merck KGaA has secured an option on UK’s F-Star Biotechnology Ltd’s preclinical bispecific PD-L1/LAG checkpoint inhibitor FS118 and four candidates in discovery stage.
Cambridge-based specialist ion channel CRO and drug discovery company Metrion Biosciences Ltd has named James Beaumont Head of Business Development. He joins from NZP-Dextra, where he held the post of Development Director.
https://european-biotechnology.com/wp-content/uploads/2024/04/james-beaumont.jpg474420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-06-02 07:44:002017-06-02 07:44:00Metrion Biosciences: Developing the business
Cambridge-based cancer company Bicycle Therapeutics has raised £40m to advance its clinical pipeline of peptide-based conjugates with antibody-like binding properties.
UK-based drug developers and contract manufacturers are set to find partners in the European Economic Area (EEA) to uphold Orphan Drug Designation, MAA or transfer their current UK based site of batch release to a location established in the Union.
https://european-biotechnology.com/wp-content/uploads/2024/04/Brexit.png606593Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-06-01 09:01:102017-06-01 09:01:10EC and EMA provide Brexit guidance
Following a private placement worth CHF3m in February, Swiss allosteric modulator specialist Addex Therapeutics has increased its capital to finance clinical studies of dipraglurant in Parkinson’s and ADX71441.
https://european-biotechnology.com/wp-content/uploads/2024/04/mark-vossenaar.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-05-30 11:06:002017-05-30 11:06:00Gyros Protein Technologies: European Marketing
Eppendorf extends its range of accessories and consumables for the epMotion® 5070, 5053 and 5075 automated Liquid Handling systems to facilitate pipetting of small volumes from 10 µL down to 200 nL.
London-based orphan drug developer AMO Pharma’s drug AMO-02 has been granted FDA fast track status as treatment for congenital myotonic dystrophy, a sub-indication muscular dystrophy.
https://european-biotechnology.com/wp-content/uploads/2024/04/AMO_Pharma.jpg400600Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-05-30 10:10:192017-05-30 10:10:19AMO Pharma receives FDA Fast Track Status
Paris-based biopharma GenSight Biologics SA named Mohamed Genead as Chief Medical Officer in early May. Most recently, Genead was Vice President & Global Therapeutic Area Head for Ophthalmology/Retina Gene Therapy at Biogen.
Merck KGaA and F-star in €1bn deal
Latest NewsGerman Merck KGaA has secured an option on UK’s F-Star Biotechnology Ltd’s preclinical bispecific PD-L1/LAG checkpoint inhibitor FS118 and four candidates in discovery stage.
Metrion Biosciences: Developing the business
AppointmentsBicycle raises £40m
Latest NewsCambridge-based cancer company Bicycle Therapeutics has raised £40m to advance its clinical pipeline of peptide-based conjugates with antibody-like binding properties.
EC and EMA provide Brexit guidance
Latest NewsUK-based drug developers and contract manufacturers are set to find partners in the European Economic Area (EEA) to uphold Orphan Drug Designation, MAA or transfer their current UK based site of batch release to a location established in the Union.
Addex further improves liquidity
Latest NewsFollowing a private placement worth CHF3m in February, Swiss allosteric modulator specialist Addex Therapeutics has increased its capital to finance clinical studies of dipraglurant in Parkinson’s and ADX71441.
Gyros Protein Technologies: European Marketing
AppointmentsGyros Protein Technologies has appointed Mark Vossenaar as Vice President, European Sales.
Improved automated Liquid Handling performance
ProductsEppendorf extends its range of accessories and consumables for the epMotion® 5070, 5053 and 5075 automated Liquid Handling systems to facilitate pipetting of small volumes from 10 µL down to 200 nL.
AMO Pharma receives FDA Fast Track Status
Latest NewsLondon-based orphan drug developer AMO Pharma’s drug AMO-02 has been granted FDA fast track status as treatment for congenital myotonic dystrophy, a sub-indication muscular dystrophy.
Biocorp partners with Virbac
Latest NewsFrench drug delivery specialist Biocorp S.A. (Issoire) has signed an industrialisation contract with Virbac, one of the top-ten vet-med makers.
GenSight Biologics: Progressing the ophthalmic pipeline
AppointmentsParis-based biopharma GenSight Biologics SA named Mohamed Genead as Chief Medical Officer in early May. Most recently, Genead was Vice President & Global Therapeutic Area Head for Ophthalmology/Retina Gene Therapy at Biogen.